Munich - Delayed Quote EUR

UCB SA (UNC.MU)

Compare
188.20
-1.40
(-0.74%)
At close: January 31 at 5:27:10 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UNC.MU

Recent News: UNC.MU

View More
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
PR Newswire 15 days ago
USNA or UCBJY: Which Is the Better Value Stock Right Now?

USNA or UCBJY: Which Is the Better Value Stock Right Now?
Zacks last month
Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study

Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study
The Wall Street Journal last month
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
PR Newswire last month
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
PR Newswire 2 months ago
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Benzinga 2 months ago
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
PR Newswire 2 months ago
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
GlobeNewswire 2 months ago
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
PR Newswire 2 months ago
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
PR Newswire 3 months ago
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
PR Newswire 3 months ago
View More

Related Tickers

1AEA.SG argenx SE
635.00
+2.42%
 
1AE.SG argenx SE
637.80
+1.75%
 
ARGX.VI argenx SE
642.80
+1.61%
 
LVTX LAVA Therapeutics N.V.
0.9800
+3.62%
 
ARGX argenx SE
655.13
-1.58%
 
CORT Corcept Therapeutics Incorporated
66.92
-4.26%
 
PPCB Propanc Biopharma, Inc.
9.00
0.00%
 
AKRO Akero Therapeutics, Inc.
54.08
-2.31%